PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

Lobbying for PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$220,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Texas

Official filing document

Government bodies contacted 5

Centers For Medicare and Medicaid Services (CMS)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 5316
Drug Shortage Compounding Patient Access Act of 2025
S 3794
SAFE Drugs Act of 2026
HR 6509
SAFE Drugs Act of 2025
S 3788
CLEAR LABELS Act

Lobbying activity 3

Pharmacy

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act

Medicare/Medicaid

Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees

Budget/Appropriations

Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.